Loading filters...
Publications per Year (398 total)
1
·
1
·
1
·
1
2000
1
·
1
·
1
·
1
·
4
2005
2
·
2
·
2
·
1
·
6
·
2
·
2
·
4
·
2
2015
14
·
20
·
16
·
25
·
26
2020
45
·
32
·
39
·
50
·
65
2025
31
·
Loaded
Click to load
50 / 398 papers loaded(scroll for more)
202612 papers
GeneralAll Stages2026
Venous invasion in upper tract urothelial carcinoma: Diagnostic features and oncologic outcomes.
Brönimann S et al. Urol Oncol. 2026
Generalearly2026
Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study.
Necchi A et al. Lancet Oncol. 2026
ADCearly2026
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Vulsteke C et al. N Engl J Med. 2026
Immunotherapyadvanced2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab.
Gebrael G et al. Bladder Cancer. 2026
FGFR alteredadvanced2026
Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.
Pant S et al. Clin Cancer Res. 2026
FGFR alteredadvanced2026
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study.
Loriot Y et al. J Clin Oncol. 2026
ImmunotherapyAll Stages2026
The Hippo Pathway is Dysregulated in Cancer-Associated Fibroblasts in Anti-PD-L1 Resistant Cancer.
Roels J et al. Cancer Res. 2026
ADCadvanced2026
Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors.
Zhu Y et al. Ann Oncol. 2026
Immunotherapyearly2026
Intratumoral Expression of a Composite B Cell / CD8 T Cell Biomarker Stratifies Overall Survival by Circulating Tumor DNA Status and Benefit From Adjuvant Immunotherapy in High-Risk Muscle-Invasive Urothelial Carcinoma.
Elias R et al. J Urol. 2026
Generaladvanced2026
Real-world treatment sequences and overall survival in metastatic bladder cancer: The STATES-Bladder study.
Moinard-Butot F et al. Urol Oncol. 2026
Immunotherapyearly2026
Radiation Therapy Combined with Immunotherapy Before Radical Cystectomy in Locally Advanced Bladder Cancer: A Prospective, Single-arm, Multicenter, Phase 2 Trial (RACE-IT).
Schmid SC et al. Eur Urol Oncol. 2026
ImmunotherapyAll Stages2026
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial.
Mellema JJ et al. Nat Med. 2026
202538 papers
Immunotherapyearly2025
Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial.
Rodríguez-Moreno JF et al. Clin Cancer Res. 2025
Immunotherapyearly2025
Challenges in Defining Clinical Complete Response to Systemic Therapy in Muscle-invasive Bladder Cancer: Insights from the EORTC STARBURST Project.
Masson-Lecomte A et al. Eur Urol Oncol. 2025
ImmunotherapyAll Stages2025
Safety and Efficacy of Neoadjuvant Durvalumab Plus Gemcitabine/Cisplatin or Carboplatin in Patients With Operable High-Risk Upper Tract Urothelial Carcinoma: The iNDUCT-GETUG V08 Trial.
Houédé N et al. J Clin Oncol. 2025
ImmunotherapyAll Stages2025
Impact of Molecular Androgen and Estrogen Response Scores on Outcomes Following Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer.
Tateo V et al. Clin Cancer Res. 2025
Immunotherapyadvanced2025
Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
Stockem CF et al. Clin Cancer Res. 2025
Immunotherapyadvanced2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial.
Grivas P et al. Eur Urol Oncol. 2025
Immunotherapyadvanced2025
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211.
Fallara G et al. Urol Oncol. 2025
ImmunotherapyAll Stages2025
Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer.
St-Laurent MP et al. Eur Urol. 2025
Immunotherapyearly2025
An RMST-based analysis of systemic therapy in muscle-invasive bladder cancer.
Venkatesh A et al. Urol Oncol. 2025
NMIBCAll Stages2025
Use of Rectal Diazepam to Prevent Bladder Spasms and Leakage of Medication During Intravesical Administration of Nadofaragene Firadenovec for Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer.
Moyer JA et al. J Urol. 2025
Immunotherapyadvanced2025
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis.
Hoffman-Censits J et al. Ann Oncol. 2025
Immunotherapyearly2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.
Galsky MD et al. Nat Med. 2025
Generaladvanced2025
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Nishimura N et al. Bladder Cancer. 2025
ImmunotherapyAll Stages2025
Avelumab and taxol chemotherapy in platinum-refractory or ineligible metastatic urothelial carcinoma (AVETAX trial).
Garje R et al. Urol Oncol. 2025
Immunotherapyearly2025
Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial.
Raychaudhuri R et al. Eur Urol. 2025
Immunotherapyadvanced2025
Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial.
Jain RK et al. Eur Urol Oncol. 2025
Generaladvanced2025
Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers.
Iida K et al. ESMO Open. 2025
NMIBCAll Stages2025
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Daneshmand S et al. J Clin Oncol. 2025
Generaladvanced2025
Early real-world utilization of avelumab switch maintenance among patients with advanced urothelial carcinoma without progression following treatment with first-line platinum-based chemotherapy.
Moon HH et al. Urol Oncol. 2025
FGFR alteredadvanced2025
Fibroblast Growth Factor Receptor Alteration Testing for >3600 Patients with Locally Advanced/Metastatic Urothelial Cancer and Non-muscle-invasive Bladder Cancer: An Analysis of the Global ANNAR Biomarker Study.
Matsubara N et al. Eur Urol Oncol. 2025
FGFR alteredadvanced2025
A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer.
Yu Y et al. Cancer Res. 2025
Generaladvanced2025
Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin Alone from the CheckMate 901 Trial.
Galsky MD et al. Eur Urol. 2025
ADCadvanced2025
Association between drug-related cutaneous adverse events and survival outcomes in patients treated with enfortumab vedotin.
Belkaïd S et al. Eur J Cancer. 2025
FGFR alteredAll Stages2025
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma.
Pichler R et al. Eur Urol Oncol. 2025
GeneralAll Stages2025
Presence of an Artificial Intelligence-powered Predictive Biomarker Is Associated with a Poor Response to Intravesical Bacillus Calmette-Guerin but Not to Intravesical Sequential Gemcitabine/Docetaxel in Patients with High-grade Non-muscle-invasive Bladder Cancer.
Packiam VT et al. Eur Urol Oncol. 2025
Generaladvanced2025
Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma.
Chow RD et al. Urol Oncol. 2025
ADCearly2025
Spatial distribution and subtype-specific expression patterns of Nectin-4 in muscle-invasive bladder cancer.
Olah C et al. BJU Int. 2025
Immunotherapyearly2025
Molecular Characterization of Residual Muscle-Invasive Bladder Cancer Identifies a Scar-Like Transcriptomic Profile with Favorable Prognosis after Neoadjuvant Therapy.
de Jong JJ et al. Clin Cancer Res. 2025
Immunotherapyearly2025
Efficacy of adjuvant nivolumab in patients with upper tract predominant urothelial carcinoma: A single-center real-world study.
Chen YC et al. Urol Oncol. 2025
Generaladvanced2025
COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.
Pal SK et al. J Clin Oncol. 2025
ADCadvanced2025
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma.
Sternschuss M et al. ESMO Open. 2025
ImmunotherapyAll Stages2025
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial.
Garcia-Del-Muro X et al. Clin Cancer Res. 2025
Immunotherapyadvanced2025
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.
Bellmunt J et al. Eur Urol. 2025
NMIBCAll Stages2025
FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette-Guérin-Unresponsive Non-Muscle-Invasive Bladder Cancer.
Colbert L et al. Clin Cancer Res. 2025
ImmunotherapyAll Stages2025
Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.
Saal J et al. JAMA Oncol. 2025
ADCadvanced2025
Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer.
P Shanmugam S et al. Bladder Cancer. 2025
Immunotherapyadvanced2025
Cost-effectiveness analysis of perioperative durvalumab plus platin-based chemotherapy in muscle invasive bladder cancer in Germany.
Rieger C et al. Eur J Cancer. 2025
Generaladvanced2025
Molecular profile and clinical impact of MDM2 amplification in patients with advanced biliary tract cancer.
Yoon H et al. ESMO Open. 2025